Pharma taps Holland & Knight ahead of orphan drug tax fight
6 hours ago · That law spared what’s known as the orphan drug tax credit from being repealed altogether, ... Caitlin worked on the social desk for ABC News’ D.C. Bureau, where she used social media to ...
Orphanews - Rare diseases newsletter
Dec 19, 2024 · OrphaNews is a freely available, twice-monthly electronic newsletter presenting an overview of scientific and political news about rare diseases and orphan drugs. OrphaNews is produced by Orphanet and is intended for the rare disease community.
Rigel announces R289 granted Orphan Drug designation by FDA …
2 days ago · Rigel Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes. R2891, Rigel’s potent and ...
Rigel Announces R289 Granted Orphan Drug Designation by the …
1 day ago · This press release contains forward-looking statements relating to, among other things, the possible advantages of Orphan Drug and Fast Track designations, the potential benefits of R289 as a therapeutic for MDS and LR-MDS, the existence of patients with an unmet medical need for such therapy, certain potential benefits associated with orphan ...
Zelasudil wins FDA orphan drug status as IPF treatment candidate
Aug 25, 2023 · Zelasudil, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s now being tested in clinical trials, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA).
FDA Grants ALG-801 Orphan Drug Designation for Treatment of …
1 day ago · The FDA announced the granting of an orphan drug designation (ODD) to ALG-801 (AliveGen) for the treatment of pulmonary arterial hypertension (PAH), a rare and life-threatening condition characterized by high blood pressure in the long arteries that could lead to right-sided heart failure, according to a news release from AliveGen. 1
The United States FDA Awards Orphan Drug Designation (ODD)
Apr 15, 2024 · The United States Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to NM5072 for the treatment of anemia in PNH patients.
S-oxprenolol granted orphan drug status by FDA as ALS treatment
Sep 6, 2024 · S-oxprenolol, an investigational therapy being developed by Actimed Therapeutics to treat muscle wasting in amyotrophic lateral sclerosis (ALS), has been granted orphan drug status in the U.S.
FDA grants orphan drug status to RAG-21 for treating FUS-ALS
Nov 25, 2024 · RAG-21, a therapy Ractigen Therapeutics is developing for amyotrophic lateral sclerosis (ALS) linked to mutations in the FUS gene, has been awarded orphan drug status by the U.S. Food and Drug Administration (FDA).
US FDA grants Orphan Drug Designation for iOnctura's first-in …
iOnctura, a pioneering, clinical-stage biotechnology company developing transformative cancer therapies, today announces that the US Food and Drug Administration (FDA) has granted Orphan Drug...
- Some results have been removed